Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Vitamin D  COVID-19 treatment studies for Vitamin D  C19 studies: Vitamin D  Vitamin D   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Hospitalization 67% Improvement Relative Risk Case 78% c19early.org/d Villasis-Keever et al. Vitamin D for COVID-19 RCT Prophylaxis Is prophylaxis with vitamin D beneficial for COVID-19? Double-blind RCT 302 patients in Mexico (July - December 2020) Fewer cases with vitamin D (p=0.0012) Villasis-Keever et al., Archives of Medical Rese.., doi:10.1016/j.arcmed.2022.04.003 Favors vitamin D Favors control
Efficacy and Safety of Vitamin D Supplementation to Prevent COVID-19 in Frontline Healthcare Workers. A Randomized Clinical Trial
Villasis-Keever et al., Archives of Medical Research, doi:10.1016/j.arcmed.2022.04.003
Villasis-Keever et al., Efficacy and Safety of Vitamin D Supplementation to Prevent COVID-19 in Frontline Healthcare Workers. A.., Archives of Medical Research, doi:10.1016/j.arcmed.2022.04.003
Apr 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
RCT 321 healthcare workers in Mexico, showing significantly lower SARS-CoV-2 infection with vitamin D prophylaxis. 4,000IU daily for 30 days.
In comparison to [Jolliffe], this study used a higher dose, the participants had much higher exposure to SARS-CoV-2 patients, and the study was prior to vaccination. In [Jolliffe], 89% of participants had received a vaccine dose by the end of the study period, and the period overlapped with increasing solar UVB.
For more discussion see [twitter.com]
risk of hospitalization, 66.5% lower, RR 0.33, p = 1.00, treatment 0 of 150 (0.0%), control 1 of 152 (0.7%), NNT 152, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), ITT.
risk of case, 78.0% lower, RR 0.22, p = 0.001, treatment 7 of 150 (4.7%), control 26 of 152 (17.1%), NNT 8.0, adjusted per study, multivariable, Table 3.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Villasis-Keever et al., 18 Apr 2022, Double Blind Randomized Controlled Trial, placebo-controlled, Mexico, peer-reviewed, 16 authors, study period 15 July, 2020 - 30 December, 2020, dosage 4,000IU daily.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperVitamin DAll
Abstract: Journal Pre-proof Efficacy and Safety of Vitamin D Supplementation to Prevent COVID-19 in Frontline Healthcare Workers. A Randomized Clinical Trial Miguel A Villasis-Keever , Mardia G López-Alarcón , Guadalupe Miranda-Novales , Jessie N Zurita-Cruz , Aly S Barrada-Vázquez , Joaquı́n González-Ibarra , Monserrat Martı́nez-Reyes , Concepción Grajales-Muñiz , Clara E Santacruz-Tinoco , Bernardo Martı́nez-Miguel , Jorge Maldonado-Hernández , Yazmı́n Cifuentes-González , Miguel Klünder-Klünder , Juan Garduño-Espinosa , Briseida López-Martı́nez , Israel Parra-Ortega PII: DOI: Reference: S0188-4409(22)00045-5 https://doi.org/10.1016/j.arcmed.2022.04.003 ARCMED 2733 To appear in: Archives of Medical Research Received date: Revised date: Accepted date: February 28, 2022 March 25, 2022 April 11, 2022 Please cite this article as: Miguel A Villasis-Keever , Mardia G López-Alarcón , Guadalupe Miranda-Novales , Jessie N Zurita-Cruz , Aly S Barrada-Vázquez , Joaquı́n González-Ibarra , Monserrat Martı́nez-Reyes , Concepción Grajales-Muñiz , Clara E Santacruz-Tinoco , Bernardo Martı́nez-Miguel , Jorge Maldonado-Hernández , Yazmı́n Cifuentes-González , Miguel Klünder-Klünder , Juan Garduño-Espinosa , Briseida López-Martı́nez , Israel Parra-Ortega , Efficacy and Safety of Vitamin D Supplementation to Prevent COVID-19 in Frontline Healthcare Workers. A Randomized Clinical Trial, Archives of Medical Research (2022), doi: https://doi.org/10.1016/j.arcmed.2022.04.003 This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. © 2022 Published by Elsevier Inc. on behalf of Instituto Mexicano del Seguro Social (IMSS). Arch Med Res 22-00242 Highlights  Due to its immunomodulatory properties, vitamin D is expected to have a role in viral infections including SARS-CoV-2  Supplementation with vitamin D in highly exposed individuals such as frontline health care workers, decreases the susceptibility for SARS-CoV-2 infection  The preventive effect of vitamin D supplementation is independent of vitamin D status  Medium doses of vitamin D (4000 IU per day) seems safe for short periods of supplementation 1 Arch Med Res 22-00242 ORIGINAL ARTICLE Vitamin D effectiveness to Prevent COVID-19 Efficacy and Safety of Vitamin D Supplementation to Prevent COVID-19 in Frontline Healthcare Workers. A Randomized Clinical Trial Miguel A Villasis-Keevera, Mardia G López-Alarcónb, Guadalupe Miranda-Novalesa, Jessie N Zurita-Cruzc, Aly S Barrada-Vázquezb, Joaquín González-Ibarrad, Monserrat Martínez-Reyesb, Concepción Grajales-Muñize, Clara E Santacruz-Tinocoe, Bernardo Martínez-Miguele, Jorge Maldonado-Hernándezb, Yazmín Cifuentes-Gonzálezb, Miguel Klünder-Klünderf, Juan GarduñoEspinosaf, Briseida López-Martínezf, Israel Parra-Ortegaf a Unidad de Investigación en Análisis y Síntesis de la Evidencia, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Ciudad de México, México b Unidad de Investigación Médica..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit